

Technology Advisory Interests Register

Topic: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Simon McNamara	TAC Committee Member	Financial	GSK have announced we will be conducting a Phase 3 trial of a new therapy (IDRX-42) against sunitinib in GIST patients who have previously been treated with one prior line of therapy (imatinib): https://clinicaltrials.gov/study/NCT07218926 . The trial is not yet recruiting. I note ripretinib is being evaluated in patients who have previously received three lines of therapy, but am unsure whether the planned GSK study in patients who have received one prior line of therapy would mean I am considered too conflicted to be able to participate in this TAC meeting.	12/12/2025	It was agreed that Simon's declaration would not prevent them from participating in discussions on this appraisal.
Dr Ramesh Bulusu	Expert	Indirect - financial	I have been on the advisory board and received remuneration for expert advice from Deciphera pharmaceuticals. 2022-2024	27/05/2025 07/01/2026	It was agreed that Dr Bulusu's declaration would not prevent them from providing expert advice to the committee